AKT1 and neoplasm: Paired analyses of the patient-matched primary tumor and BM has implicated that the activation of the PI3K/AKT/mTOR pathway and cyclin-dependent kinase (CDK) pathway may represent a site-specific contributor to BM development [17, 18].